CompanyHealthAi
Terran Biosciences
Terran Biosciences is a platform biotech developing therapeutics and technologies for neurological and psychiatric disease. It runs one of the industry's largest psychedelic development programs - psilocybin, LSD, MDMA derivatives and novel prodrugs - alongside late-stage schizophrenia assets licensed from Sanofi and Pierre Fabre, GMP psychedelic manufacturing, and NM-101, an FDA-cleared cloud platform for neuromelanin MRI analysis.
2017Founded
MiamiHQ
Part of ~$12.8M total reportedSeries B
biotechneurosciencepsychedelicsdrug-developmentschizophreniapsilocybin